Early On-treatment Circulating Tumor DNA Measurements and Response to Immune Checkpoint Inhibitors in Advanced Urothelial Cancer

Sofie H. Tolmeijer,Sandra van Wilpe,Maartje J. Geerlings,Daniel von Rhein,Tineke J. Smilde,Iris S.H. Kloots,Harm Westdorp,Mustafa Coskuntürk,Irma M. Oving,Jolique A. van Ipenburg, Antoine G. van der Heijden,Tom Hofste, Marjan M. Weiss,Jack A. Schalken,Winald R. Gerritsen,Marjolijn J.L. Ligtenberg,Niven Mehra

European Urology Oncology（2023）

引用 0|浏览8

暂无评分

摘要

Early changes in circulating tumor DNA (ctDNA) levels during immunotherapy strongly associate with therapy response and survival of patients with advanced urothelial cancer. These results justify prospective studies to evaluate switching or intensifying therapy based on early on-treatment ctDNA changes.

查看译文

关键词

Biomarker,Circulating tumor DNA,Genomics,Immune checkpoint inhibitors,Immunotherapy,Liquid biopsy,Urothelial cancer

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要